TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Starpharma Holdings Limited ( (AU:SPL) ) has provided an update.
Starpharma Holdings Limited has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year under the Australian Federal Government’s program. This incentive is crucial for Starpharma as it continues to invest in high-impact R&D programs, strengthening its position in the global biotechnology sector and supporting the advancement of its dendrimer technology towards commercialization and global patient benefit.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company with over two decades of experience in advancing dendrimer technology from the lab to the patient. The company focuses on improving health outcomes for patients with significant illnesses, such as cancer, through its unique dendrimer technology. Starpharma’s portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, research collaborations, and commercially marketed over-the-counter products.
Average Trading Volume: 397,361
Technical Sentiment Signal: Hold
Current Market Cap: A$52.28M
For detailed information about SPL stock, go to TipRanks’ Stock Analysis page.